Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 9:2022:8949048.
doi: 10.1155/2022/8949048. eCollection 2022.

Diagnostic Values of Advanced Glycation End Products and Homocysteine in Patients with Alzheimer's Disease and Sarcopenia

Xuelian Zhang  1 , Yunxia Meng  1 , Weiwei Zhang  1 , Luhang Shi  1 , Xia Liu  1 , Lijuan Zhang  1 , Qiaoling Liu  1
Affiliations

Diagnostic Values of Advanced Glycation End Products and Homocysteine in Patients with Alzheimer's Disease and Sarcopenia

Xuelian Zhang et al. Comput Math Methods Med. .

Retraction in

Abstract

This study is aimed at exploring the diagnostic value of advanced glycation end products (AGEs) and homocysteine (Hcy) in Alzheimer's disease (AD) complicated with sarcopenia (SP) and to analyze the risk factors related to AD complicated with SP. A total of 168 patients admitted to our hospital from November 2019 to December 2021 were enrolled. Patients were divided into the NC (no SP and AD) group with 29 cases, the AD group with 39 cases, the AD+SP group with 35 cases, and the SP group with 65 cases. The general information, Mini-Mental State Examination (MMSE) scores, and serum levels of AGEs and Hcy among the four groups were compared. Unordered logistic regression was used to analyze the influencing factors of SP patients complicated with dementia. The AGE level was higher in the AD or AD+SP group than the NC or SP group (P < 0.05). There was no significant difference between the SP group and the NC group or between the AD group and the AD+SP group (P > 0.05). The Hcy level was higher in the SP or AD group than the NC group (P < 0.05). There were no significant differences between the AD group and NC group or between the SP group and AD+SP group (P > 0.05). The ROC curve of serum AGEs and Hcy for the diagnosis of AD showed that the area under curve (AUC) was 0.887, P < 0.05 (95% CI: 0.821-0.954, sensitivity: 80.95%, specificity: 73.81%) and 0.7423, P < 0.05 (95% CI: 0.6382-0.8465, sensitivity: 60.42%, specificity: 57.59%), respectively. The ROC curve of serum AGEs and Hcy for the diagnosis of SP showed that the AUC was 0.5533, P > 0.05 (95% CI: 0.4294-0.6771) and 0.8744, P < 0.05 (95% CI: 0.8006-0.9483). Age (P < 0.001), depression (P = 0.001), malnutrition (P = 0.002), and BMI (P < 0.001) were independent influencing factors of SP complicated with AD in elderly inpatients. In conclusion, combined serum AGEs and Hcy had a good diagnostic value for AD combined with SP, which may be helpful for early detection of patient condition.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Serum AGEs level in four groups. Note: ∗P < 0.05, vs. the NC group; #P < 0.05, vs. the SP group.
Figure 2
Figure 2
Serum Hcy level in four groups. Note: ∗P < 0.05, vs. the NC group.
Figure 3
Figure 3
ROC curve of AGEs for the diagnosis of AD and SP.
Figure 4
Figure 4
ROC curve of serum Hcy for the diagnosis of AD and SP.
Figure 5
Figure 5
ROC curve of combined AGEs and Hcy for the diagnosis of AD and SP.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nau J. Y. 100 years later, what to know about Maillard reaction and French fries toxicity? Revue Médicale Suisse . 2014;10(424):772–773. - PubMed
    1. Khachaturian Z. S. Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease. Alzheimers Dement . 2011;7(3):253–256. doi: 10.1016/j.jalz.2011.04.003. - DOI - PubMed
    1. Chen L. K., Woo J., Assantachai P., et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. Journal of the American Medical Directors Association . 2020;21(3):300–307.e2. doi: 10.1016/j.jamda.2019.12.012. - DOI - PubMed
    1. Beaudart C., Zaaria M., Pasleau F., Reginster J. Y., Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One . 2017;12(1, article e0169548) doi: 10.1371/journal.pone.0169548. - DOI - PMC - PubMed
    1. Jakus V., Bauerová K., Rietbrock N. Effect of aminoguanidine and copper (II) ions on the formation of advanced glycosylation end products. In vitro study on human serum albumin. Arzneimittel-Forschung . 2001;51(4):280–283. - PubMed

Publication types

Substances